Literature DB >> 32989606

Reduced H3K27me3 levels in diffuse gliomas: association with 1p/19q codeletion and difference from H3K27me3 loss in malignant peripheral nerve sheath tumors.

Keiichiro Kitahama1, Shohei Iijima2, Ayumi Sumiishi1, Akimasa Hayashi1, Kiyotaka Nagahama1, Kuniaki Saito2, Nobuyoshi Sasaki2, Keiichi Kobayashi2, Saki Shimizu2, Motoo Nagane2, Junji Shibahara3.   

Abstract

Trimethylation of histone H3 at lysine 27 (H3K27me3) acts as a transcriptional repressor of target genes. Recent immunohistochemical studies have reported a loss of H3K27me3 modification in diffuse (especially 1p/19q-codeleted) gliomas. However, we did not observe H3K27me3 loss in diffuse gliomas using routine immunostaining conditions for the detection of H3K27me3 loss in malignant peripheral nerve sheath tumors (MPNSTs). Therefore, we conducted immunohistochemical analysis of surgically resected specimens to understand the differences in the H3K27me3 status in MPNSTs and diffuse gliomas and evaluate the diagnostic utility of H3K27me3 immunohistochemistry. Staining with a standard 1:200 dilution of the C36B11 antibody showed a complete loss of H3K27me3 in 5 out of 11 MPNSTs, whereas most diffuse gliomas (149/151, 98.7%) showed diffuse immunoreactivity. At a 1:2000 antibody dilution, 12.6% (19/151) of the diffuse gliomas showed H3K27me3 loss, which was significantly associated with 1p/19q codeletion (P < 0.001). H3K27me3 loss predicted 1p/19q codeletion in IDH-mutant gliomas with lower sensitivity (56.2%) and higher specificity (100%) than ATRX retention or p53 negative result. In conclusion, reduction in H3K27me3 levels was associated with 1p/19q codeletion in diffuse gliomas; however, the extent of reduction differed from that in MPNSTs, and the results depended on the immunostaining conditions.

Entities:  

Keywords:  1p/19q codeletion; Diffuse glioma; H3K27me3; Immunohistochemistry; MPNST

Mesh:

Substances:

Year:  2020        PMID: 32989606     DOI: 10.1007/s10014-020-00382-y

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  4 in total

1.  Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.

Authors:  Umma Habiba; Hirokazu Sugino; Roumyana Yordanova; Koki Ise; Zen-Ichi Tanei; Yusuke Ishida; Satoshi Tanikawa; Shunsuke Terasaka; Ken-Ichi Sato; Yuuta Kamoshima; Masahiko Katoh; Motoo Nagane; Junji Shibahara; Masumi Tsuda; Shinya Tanaka
Journal:  Acta Neuropathol Commun       Date:  2021-05-21       Impact factor: 7.578

Review 2.  Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas.

Authors:  Nikolaus von Knebel Doeberitz; Daniel Paech; Dominik Sturm; Stefan Pusch; Sevin Turcan; Yogen Saunthararajah
Journal:  Int J Cancer       Date:  2022-06-16       Impact factor: 7.316

3.  H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.

Authors:  Aldo Scarpa; Valeria Barresi; Serena Ammendola; Nicolò Caldonazzi; Michele Simbolo; Maria Liliana Piredda; Matteo Brunelli; Pietro Luigi Poliani; Giampietro Pinna; Francesco Sala; Claudio Ghimenton
Journal:  Virchows Arch       Date:  2021-06-24       Impact factor: 4.535

Review 4.  The metabolomic landscape plays a critical role in glioma oncogenesis.

Authors:  Kenta Masui; Webster K Cavenee; Paul S Mischel; Noriyuki Shibata
Journal:  Cancer Sci       Date:  2022-03-23       Impact factor: 6.518

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.